

Christian Herzog

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8955533/publications.pdf>

Version: 2024-02-01

31
papers

811
citations

430754

18
h-index

501076

28
g-index

32
all docs

32
docs citations

32
times ranked

876
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical, serological and epidemiological features of hepatitis A in León, Nicaragua. <i>PeerJ</i> , 2021, 9, e11516.	0.9	0
2	Immune memory persistence is well documented for hepatitis A vaccines. <i>Vaccine</i> , 2021, 39, 4775-4776.	1.7	3
3	Hepatitis A vaccination and its immunological and epidemiological long-term effects – a review of the evidence. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 1496-1519.	1.4	29
4	Safety and immunogenicity of tetanus/diphtheria vaccination in patients with rheumatic diseases – a prospective multi-centre cohort study. <i>Rheumatology</i> , 2019, 58, 1585-1596.	0.9	19
5	Hepatitis A vaccination in immunocompromised patients – the need for individualized vaccination strategies and correct methodology. <i>Travel Medicine and Infectious Disease</i> , 2019, 32, 101526.	1.5	1
6	An extra priming dose of hepatitis A vaccine to adult patients with rheumatoid arthritis and drug induced immunosuppression – A prospective, open-label, multi-center study. <i>Travel Medicine and Infectious Disease</i> , 2018, 21, 43-50.	1.5	29
7	Serologic differential diagnosis of hepatitis A virus (HAV) infected and vaccinated individuals: How long persist antibodies to non-structural HAV proteins?. <i>Vaccine</i> , 2018, 36, 3883-3884.	1.7	1
8	Successful comeback of the single-dose live oral cholera vaccine CVD 103-HgR. <i>Travel Medicine and Infectious Disease</i> , 2016, 14, 373-377.	1.5	19
9	Single-Dose Hepatitis A Immunization: 7.5-Year Observational Pilot Study in Nicaraguan Children to Assess Protective Effectiveness and Humoral Immune Memory Response. <i>Journal of Infectious Diseases</i> , 2016, 214, 1498-1506.	1.9	25
10	Changing from whole-cell to acellular pertussis vaccines would trade superior tolerability for inferior protection. <i>Expert Review of Vaccines</i> , 2015, 14, 1065-1072.	2.0	3
11	Influence of parenteral administration routes and additional factors on vaccine safety and immunogenicity: a review of recent literature. <i>Expert Review of Vaccines</i> , 2014, 13, 399-415.	2.0	48
12	Cross-reactive immune response elicited by parenteral Vi polysaccharide typhoid vaccine against non-typhoid Salmonellae. <i>Vaccine</i> , 2014, 32, 544-551.	1.7	10
13	Hepatitis A vaccine for immunosuppressed patients with rheumatoid arthritis: A prospective, open-label, multi-centre study. <i>Travel Medicine and Infectious Disease</i> , 2014, 12, 134-142.	1.5	67
14	Decreasing Risk of Hepatitis A Infection in León, Nicaragua: Evidence from Cross-Sectional and Longitudinal Seroepidemiology Studies. <i>PLoS ONE</i> , 2014, 9, e87643.	1.1	9
15	Kinetics of maternally acquired anti-hepatitis A antibodies: Prediction of waning based on maternal or cord blood antibody levels. <i>Vaccine</i> , 2013, 31, 1490-1495.	1.7	22
16	Surveying adverse event rates: lessons from a virosomal hepatitis A vaccine. <i>Expert Review of Vaccines</i> , 2012, 11, 383-385.	2.0	1
17	The phylogeny of yellow fever virus 17D vaccines. <i>Vaccine</i> , 2012, 30, 989-994.	1.7	29
18	Real-life versus package insert: A post-marketing study on adverse-event rates of the virosomal hepatitis A vaccine Epaxal® in healthy travellers. <i>Vaccine</i> , 2011, 29, 5000-5006.	1.7	12

#	ARTICLE	IF	CITATIONS
19	Successful Memory Response following a Booster Dose with a Virosome-Formulated Hepatitis A Vaccine Delayed Up to 11 Years. <i>Vaccine Journal</i> , 2011, 18, 885-887.	3.2	38
20	Predicted 30-year protection after vaccination with an aluminum-free virosomal hepatitis A vaccine. <i>Journal of Medical Virology</i> , 2010, 82, 1629-1634.	2.5	43
21	Virosomal Hepatitis A Vaccine: Comparing Intradermal and Subcutaneous With Intramuscular Administration. <i>Journal of Travel Medicine</i> , 2009, 16, 413-419.	1.4	30
22	Concomitant Administration of a Virosome-Adjuvanted Hepatitis A Vaccine With Routine Childhood Vaccines at Age Twelve to Fifteen Months: A Randomized Controlled Trial. <i>Pediatric Infectious Disease Journal</i> , 2007, 26, 787-793.	1.1	34
23	Immunogenicity and Safety of a Pediatric Dose of a Virosome-Adjuvanted Hepatitis A Vaccine. <i>Pediatric Infectious Disease Journal</i> , 2007, 26, 705-710.	1.1	34
24	Rate, intensity, and duration of local reactions to a virosome-adjuvanted vs. an aluminium-adsorbed hepatitis A vaccine in UK travellers. <i>Travel Medicine and Infectious Disease</i> , 2006, 4, 313-318.	1.5	36
25	Immunogenicity and Safety of a Virosomal Hepatitis A Vaccine (Epaxal®) in the Elderly. <i>Journal of Travel Medicine</i> , 2006, 13, 78-83.	1.4	69
26	Reduced-Dose Intradermal Vaccination against Hepatitis A with an Aluminum-Free Vaccine Is Immunogenic and Can Lower Costs. <i>Clinical Infectious Diseases</i> , 2005, 41, 1537-1540.	2.9	34
27	IMMUNOGENICITY AND SAFETY OF BERNA-YF COMPARED WITH TWO OTHER 17D YELLOW FEVER VACCINES IN A PHASE 3 CLINICAL TRIAL. <i>American Journal of Tropical Medicine and Hygiene</i> , 2005, 72, 339-346.	0.6	45
28	Successful Booster Antibody Response up to 54 Months after Single Primary Vaccination with Virosome-Formulated, Aluminum-Free Hepatitis A Vaccine. <i>Clinical Infectious Diseases</i> , 2003, 37, e126-e128.	2.9	27
29	Efficacy of Virosome Hepatitis A Vaccine in Young Children in Nicaragua: Randomized Placebo-Controlled Trial. <i>Journal of Infectious Diseases</i> , 2003, 188, 671-677.	1.9	67
30	Detection of antibodies to HAV 3C proteinase in experimentally infected chimpanzees and in naturally infected children. <i>Vaccine</i> , 2001, 19, 2878-2883.	1.7	17
31	Compatible Concurrent Administration of Yellow Fever 17D Vaccine with Oral, Live, Attenuated Cholera CVD103-HgR and Typhoid Ty21a Vaccines. <i>Journal of Infectious Diseases</i> , 1999, 179, 522-524.	1.9	9